Hybridization News and Research

RSS

Scientists define genetic cause for two types of birth defects in newborn boys

Baylor College of Medicine scientists defined a previously unrecognized genetic cause for two types of birth defects found in newborn boys, described in a report published today in the journal Nature Medicine.

2 Jun 2014

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.

31 May 2014

Researchers use molecular diagnostic methods to detect cancer

The ABC Medical Center, located in Mexico City, implemented various molecular diagnostic methods that can detect the genetic alterations in several types of cancer, so they can select a personalized therapy for each patient and direct it against the mutated genes that cause disease.

13 May 2014

NSHOA and Caris Life Sciences collaborate to establish personalized cancer care program

North Shore Hematology Oncology Associates and Caris Life Sciences today announced a collaboration to establish a personalized cancer care program for patients in the greater Long Island area.

12 May 2014

Leica and Affymetrix launch fully automated RNA in situ hybridization assays

Affymetrix, Inc. (NASDAQ:AFFX) and Leica Biosystems announce the launch of Affymetrix' fully automated RNA in situ hybridization assays ViewRNATM eZ Assays on the Leica BOND RX staining platform.

8 May 2014

Study: Routine testing with FISH and IHC may enhance detection of ALK-positive NSCLC

The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC).

25 Feb 2014

Researchers develop novel technique for detecting ALK rearrangements in non-small cell lung cancers

Researchers have developed a novel technique for detecting ALK rearrangements in non-small cell lung cancers (NSCLCs) that is more sensitive and easier to perform than currently available techniques.

25 Feb 2014

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.

30 Jan 2014

New Chromatrap Enzymatic Shearing Kit announced by Porvair Sciences

Porvair Sciences has announced a new Chromatrap Enzymatic Shearing Kit that contains all the necessary reagents and buffers for up to 10 chromatin preparations.

From Chromatrap® - Porvair Sciences Ltd 27 Jan 2014

Genetically targeted drugs used for lung cancer may also have applications in colorectal cancer patients

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.

17 Dec 2013

Genomic tests help in selecting the most effective therapy for breast cancer

Genomic tests that determine the molecular subtype of a woman's breast cancer provide a more precise prognosis and valuable guidance about the best treatment, according to new research led by Massimo Cristofanilli, M.D, Director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals.

13 Dec 2013

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

13 Dec 2013

Four-drug regimen shows first-line efficacy in advanced NSCLC

A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report.

2 Dec 2013

Habitual dietary intake of monozygotic twins associated with fecal microbiota composition

The establishment of microbial populations in the gastrointestinal-tract is a complex process, involving microbial and host interactions eventually resulting in a dense and stable population.

18 Nov 2013

Agilent collaborates with Baylor College of Medicine to provide CGH microarrays to researchers

Agilent Technologies Inc. has announced it is collaborating with Baylor College of Medicine's Medical Genetics Laboratories to provide customized CGH (comparative genomics hybridization) microarrays to researchers worldwide. Six new microarray designs unite the power of Baylor's data-rich expertise in genetics research with Agilent's microarray manufacturing capabilities to enable advanced discoveries in cancer and cytogenetics research.

12 Nov 2013

Scientists identify new algorithm to distinguish two subtypes of malignant melanoma

Scientists of the University of Ulm and Columbia University have discovered a diagnostic algorithm to distinguish two subtypes of malignant melanoma. Desmoplastic and spindle cell melanoma may look alike - they often resemble little scars or retractions of the skin - but differ in prognosis and therapeutic options.

4 Nov 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

New method to monitor activity of gene promoters during response to drug

When developing new drugs, monitoring cellular responses to candidate compounds is essential for assessing their efficacy and safety. Researchers from the RIKEN Center for Life Science Technologies report a new method to monitor and quantify the activity of gene promoters during the response to a drug, using the advanced gene expression analysis method CAGE followed by single-molecule sequencing.

3 Oct 2013